← Back to Analyst Consensus 
RCUS Buy
Arcus Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 19
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 4 reiterations from 5 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Oct 21, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Oct 21, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Oct 16, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Oct 14, 2026 | JP Morgan | initiate | — → Overweight | — | 54% |
| Sep 30, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 16, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| Sep 8, 2026 | Truist Securities | reiterate | Buy → Buy | — | 54% |
| Aug 6, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Aug 6, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 20, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 4, 2026 | LifeSci Capital | initiate | — → Outperform | — | 57% |
| May 11, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| May 7, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Apr 2, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 5, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 2, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Mar 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 12, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | $23 | 54% |
| Jan 13, 2026 | Goldman Sachs | upgrade | Neutral → Buy | $28 | 54% |
| Jan 8, 2026 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $20 | 54% |
| Dec 12, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $32 | 44% |
| Nov 28, 2025 | B of A Securities | maintain | Neutral → Neutral | $26 | 53% |
| Oct 30, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $16 | 54% |
| Oct 29, 2025 | Citigroup | maintain | Buy → Buy | $56 | 54% |
| Oct 29, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $28 | 44% |
| Oct 20, 2025 | Wells Fargo | maintain | Overweight → Overweight | $29 | 54% |
| Oct 13, 2025 | Citigroup | maintain | Buy → Buy | $54 | 54% |
| Oct 7, 2025 | Truist Securities | reiterate | Buy → Buy | $39 | 54% |
| Aug 7, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $23 | 54% |
| Aug 7, 2025 | Wells Fargo | maintain | Overweight → Overweight | $25 | 54% |
| May 9, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $22 | 54% |
| May 8, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $13 | 54% |
| May 7, 2025 | Wells Fargo | maintain | Overweight → Overweight | $26 | 54% |
| Apr 23, 2025 | Barclays | maintain | Overweight → Overweight | $14 | 53% |
| Feb 26, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $24 | 44% |
| Feb 19, 2025 | B of A Securities | maintain | Neutral → Neutral | $17 | 53% |
| Feb 18, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $18 | 44% |
| Feb 18, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $25 | 54% |
| Nov 6, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $20 | 44% |
| Oct 25, 2024 | Barclays | maintain | Overweight → Overweight | $29 | 53% |
| Oct 24, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $20 | 44% |
| Oct 21, 2024 | HC Wainwright & Co. | initiate | — → Neutral | $20 | 44% |
| Oct 8, 2024 | Wells Fargo | initiate | — → Overweight | $29 | 54% |
| Oct 7, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Oct 3, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Oct 3, 2024 | Wedbush | reiterate | Outperform → Outperform | $30 | 58% |
| Aug 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Aug 9, 2024 | Wedbush | reiterate | Outperform → Outperform | $30 | 58% |
| Aug 9, 2024 | B of A Securities | maintain | Neutral → Neutral | $23 | 53% |
Price Target Trend
Apr 26, 2026 Oct 26, 2026
EPS Estimates
+1q —
0y —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days